An intriguing observation in our study was that, initially, EGFR CAR T cells displayed a pronounced proliferation at the tumor site followed by a decay of the bioluminescent signal indicating a reduction of intratumoral CAR T cells in the second half of the therapy. Here, EGFR is linked to neoplasm.